Alopecia Areata: current and emerging treatment options

Alopecia areata is an autoimmune condition that can cause patchy hair loss anywhere on the body, though it most often affects the scalp. The medical name for baldness or hair loss is "alopecia," and "areata" denotes that it happens in small, sporadic patches. Loss of immunological privilege in hair follicles causes the condition, and CD8+NKG2D+ T cells release cytokines such as interleukin-15 (IL-15) and interferon-gamma (IFN-γ). They cause inflammation and disrupt normal hair growth by activating the JAK-STAT pathway. The severity of the illness determines the course of treatment. For localised AA, topical and intralesional corticosteroids—especially intralesional triamcinolone—remain widely utilised. Adjunctive treatments include topical minoxidil, bimatoprost, latanoprost, and anthralin. Although side effects and frequent clinic visits may restrict their usage, contact immunotherapy using diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE) may be considered for widespread disease. JAK inhibitors have emerged from our growing understanding of the JAK-STAT pathway and represent a significant development in the treatment of AA. The JAK1/JAK2 inhibitor baricitinib, which is licensed for severe AA in adults, showed notable scalp hair regeneration in phase 3 trials. The JAK3/TEC-family kinase inhibitor ritlecitinib has shown sustained long-term effects and is approved for use in adults and adolescents ≥12 years of age. SALT scores have also significantly improved with the specific JAK1/JAK2 inhibitor deuruxolitinib. Other medications, including upadacitinib, brepocitinib, and tofacitinib, are being studied or utilised in specific contexts. Upper respiratory infections, acne, headaches, and test abnormalities such as elevated cholesterol and creatine phosphokinase are common side effects of JAK inhibitors. It is advised to keep an eye on blood counts, liver enzymes, cholesterol, and infection status. Despite these developments, long-term safety, non-response, relapse upon therapy discontinuation, and cost continue to be significant obstacles. New immune-targeted therapies and customised maintenance therapy are the key topics of future research. All things considered, patients with severe AA now have a far wider range of treatment options due to targeted JAK inhibition.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24423151
Primary Topic
Hair Growth and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Alopecia Areata: current and emerging treatment options

Fahima Ayisha Aathika, Neha
Zenodo (CERN European Organization for Nuclear Research)
Hair Growth and Disorders
article

Alopecia Areata: current and emerging treatment options

Fahima Ayisha Aathika, Neha
article en

Abstract

Alopecia areata is an autoimmune condition that can cause patchy hair loss anywhere on the body, though it most often affects the scalp. The medical name for baldness or hair loss is "alopecia," and "areata" denotes that it happens in small, sporadic patches. Loss of immunological privilege in hair follicles causes the condition, and CD8+NKG2D+ T cells release cytokines such as interleukin-15 (IL-15) and interferon-gamma (IFN-γ). They cause inflammation and disrupt normal hair growth by activating the JAK-STAT pathway. The severity of the illness determines the course of treatment. For localised AA, topical and intralesional corticosteroids—especially intralesional triamcinolone—remain widely utilised. Adjunctive treatments include topical minoxidil, bimatoprost, latanoprost, and anthralin. Although side effects and frequent clinic visits may restrict their usage, contact immunotherapy using diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE) may be considered for widespread disease. JAK inhibitors have emerged from our growing understanding of the JAK-STAT pathway and represent a significant development in the treatment of AA. The JAK1/JAK2 inhibitor baricitinib, which is licensed for severe AA in adults, showed notable scalp hair regeneration in phase 3 trials. The JAK3/TEC-family kinase inhibitor ritlecitinib has shown sustained long-term effects and is approved for use in adults and adolescents ≥12 years of age. SALT scores have also significantly improved with the specific JAK1/JAK2 inhibitor deuruxolitinib. Other medications, including upadacitinib, brepocitinib, and tofacitinib, are being studied or utilised in specific contexts. Upper respiratory infections, acne, headaches, and test abnormalities such as elevated cholesterol and creatine phosphokinase are common side effects of JAK inhibitors. It is advised to keep an eye on blood counts, liver enzymes, cholesterol, and infection status. Despite these developments, long-term safety, non-response, relapse upon therapy discontinuation, and cost continue to be significant obstacles. New immune-targeted therapies and customised maintenance therapy are the key topics of future research. All things considered, patients with severe AA now have a far wider range of treatment options due to targeted JAK inhibition.

Zenodo (CERN European Organization for Nuclear Research)
Hair Growth and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Alopecia Areata: current and emerging treatment options — Fahima Ayisha Aathika, Neha · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS